ReviewEpilepsia open2026
Lipid-based Nano-delivery systems as a promising strategy for the treatment of epilepsy: Current status and challenges.
Review in Epilepsia open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEpilepsy is a prevalent chronic neurological disorder characterized by abnormal neuronal electrical activity. The primary treatment modality for individuals with epilepsy (PWE) is antiseizure medication (ASM). The multiple potential factors contributing to treatment resistance in epilepsy may be attributed to the inability of ASMs to traverse the blood-brain barrier (BBB). Consequently, it is imperative to identify a solution, and optimally, enhance ASM efficacy.
methodInnovative drug delivery technologies have shown improved therapeutic efficacy in the treatment of epilepsy as compared with traditional pharmaceutical treatments. Furthermore, exosomes, neosomes, and phytosomes have received interest as potential next-generation drug delivery platforms, owing to their benefits over semi-synthetic and synthetic alternatives. These systems have demonstrated better bioavailability, tailored distribution, and decreased adverse effects, giving them potential choices for boosting the treatment of numerous disorders.
resultsExploring and optimizing novel drug delivery systems could lead to significant advancements in the treatment of drug-resistant epilepsy by enhancing the delivery of ASMs to the brain and overcoming barriers like the BBB. Additionally, further research into the mechanisms of action and potential side effects of these innovative drug delivery systems is crucial for their successful clinical translation in epilepsy treatment. SIGNIFICANT: Pharmacokinetics and pharmacodynamic can be used to better customize medicines for specific patients, increase efficacy, and lessen side effects. All things considered, the creation of medication delivery systems based on nanotechnology has enormous potential to transform the treatment of epilepsy and enhance patient outcomes. PLAIN LANGUAGE SUMMARY: Epilepsy is a common neurological illness treated mostly with antiseizure drugs (ASMs), although treatment resistance is typically connected to the difficulty of ASMs to penetrate the blood-brain barrier (BBB). Innovative drug delivery systems, such as exosomes, neosomes, and phytosomes, offer potential advantages over existing approaches by boosting bioavailability, distribution, and minimizing side effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.